Editing Laxative (section)

===Serotonin agonist===
These are motility stimulants that work through activation of [[serotonin|5-HT<sub>4</sub>]] receptors of the [[enteric nervous system]] in the [[gastrointestinal tract]]. However, some have been discontinued or restricted due to potentially harmful cardiovascular side effects.

[[Tegaserod]] (brand name [[Zelnorm]]) was removed from the general U.S. and Canadian markets in 2007, due to reports of increased risks of heart attack or stroke. It is still available to physicians for patients in emergency situations that are life-threatening or require hospitalization.<ref>{{cite web|url=https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm|title=Postmarket Drug Safety Information for Patients and Providers - Zelnorm (tegaserod maleate) Information|first=Center for Drug Evaluation and|last=Research|website=www.fda.gov|access-date=14 April 2018}}</ref>

[[Prucalopride]] (brand name Resolor) is a current drug approved for use in the EU since October 15, 2009,<ref>{{cite web|url=http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001012/WC500053995.pdf|title=European Medicines Agency EPAR summary for the public|website=europa.eu|access-date=14 April 2018|archive-date=14 April 2018|archive-url=https://web.archive.org/web/20180414233759/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001012/WC500053995.pdf|url-status=dead}}</ref> in Canada (brand name Resotran) since December 7, 2011,<ref>{{cite web|url=http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2012_resotran_141157-eng.php#a2|title=Health Canada, Notice of Decision for Resotran|website=hc-sc.gc.ca|access-date=14 April 2018|archive-url=https://web.archive.org/web/20170318120956/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2012_resotran_141157-eng.php#a2|archive-date=18 March 2017|url-status=dead}}</ref> and in the United States since December 2018.